Questions about Atrial Fibrillation? Get answers from our expert.

Regadenoson Pregnancy and Breastfeeding Warnings

Regadenoson is also known as: Lexiscan

Regadenoson Pregnancy Warnings

Regadenoson has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of reduced fetal body weights and significant ossification delays in fore- and hind limb phalanges and metatarsals; however, maternal toxicity also occurred at these doses. Skeletal variations were increased in all treated groups. There are no controlled data in human pregnancy. Regadenoson should only be given during pregnancy when benefits outweigh risks.

It is not clear whether malformations that occurred at maternally toxic doses of regadenoson in animal species were due to fetal drug effects or only to the maternal toxic effects.

Regadenoson Breastfeeding Warnings

Based on the pharmacokinetics of regadenoson, it should be cleared 10 hours after administration. Therefore, nursing women may consider interrupting nursing for 10 hours after administration.

There are no data on the excretion of regadenoson into human milk. Because many drugs are excreted into human milk and because of the potential for serious adverse reactions from regadenoson in nursing infants, the decision to interrupt nursing after administration of regadenoson or not to administer regadenoson, should take into account the importance of the drug to the mother.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web5)